Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

Obstructive Sleep Apnea Clinical Trial

— TOP-CPAP  

Official title:

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP): a Pilot Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05951023
• Other study ID #: 190560
• Secondary ID: 277-JF-22
• Status: Recruiting
• Phase: Phase 2
• Start date: August 31, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: December 2023
• Source: University of California, San Diego
• Contact: Pamela DeYoung, RPSGT
• Phone: 858 246 2183
• Email: sleepresearch[@]health.ucsd.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

More than 10% of the US population have obstructive sleep apnea (OSA). Standard of care is therapy with CPAP (continuous positive airway pressure) which virtually eliminates OSA. However, most patients use CPAP only for part of the night (4-5hours) and about 50% patients discontinue CPAP long-term. Alternative therapies are limited, thus many OSA patients remain at risk of OSA sequelae (e.g. sleepiness, memory issues, high blood pressure, etc.). Importantly, different patients get OSA for different reasons, and recent data show that some of the underlying causes of OSA ("endotypes") such as having a low arousal threshold (i.e. waking up easily) are associated with lower CPAP adherence. Using a randomized controlled trial design, this will be the first study using a targeted intervention to manipulate the underlying OSA causes (i.e., giving a safe hypnotic to patients with OSA to increase the arousal threshold) to test the hypothesis that endotype-targeted therapy increases CPAP-adherence in patients who have low but continued CPAP usage. Ultimately, this strategy may improve the care and outcomes of millions of undertreated OSA patients.

Description:

This double-blind, randomized, placebo-controlled, single-center, phase II trial, will test if endotype-targeted drug therapy increases CPAP adherence. Patients with low CPAP adherence (i.e. CPAP use 0.5-4h/night) will be randomized in parallel to CPAP+Eszopiclone vs CPAP+Placebo for 2 weeks. The primary outcome is mean TimeOnCPAP/night on days 2-14 after initiation of study drugs. Aim 1: To test the effect of eszopiclone on CPAP usage in unselected OSA patients with low CPAP adherence. Hypothesis 1: Eszopiclone improves CPAP usage more than placebo. Aim 2: To test the effect of eszopiclone on CPAP usage in OSA patients with a low vs a high arousal threshold (ArTH) endotype. Hypothesis 2: Eszopiclone improves CPAP usage substantially more in OSA patients with a low vs a high ArTH. Further, this study will explore the mechanisms through which eszopiclone may affect CPAP usage, the effect of eszopiclone on underlying sleep apnea severity, and if the intervention and its potential effects on adherence translate into changes in clinically important outcomes (i.e., vigilance and sleepiness).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Ages 21-65 years old
• Body Mass Index <32 kg/m^2
• Physician diagnosis of OSA (AHI = 10) based on a clinical sleep study within the past 2 years (subjects who report a history of sleep apnea but do not have a sleep study report from the past 2 years available will be offered an overnight home sleep apnea test to verify OSA diagnosis)
• AHI>5/h on the overnight research sleep study #1
• Subject had the opportunity to use CPAP for at least 1 month
• Continuous positive airway pressure (CPAP) data can be queried remotely and shows usage 0.5-4h/night (based on most recent 30 day period)
• Interest to continue trying CPAP

Exclusion Criteria:

• "SAVE CPAP Side Effect Score" >3 (1 point for each: dry mouth, nasal symptoms, CPAP pressure intolerance, claustrophobia, noise problems, soreness/skin irritation, mask fit/leak problems)
• Any high-risk features: Epworth sleepiness score =18, safety-critical profession (e.g., commercial driver), prior sleep-related car accident, substantial hypoxemia during sleep [SpO2<70% for >5min] or awake [SpO2<92%]
• Any uncontrolled medical/psychiatric condition, or safety concern based on MD judgment
• Pregnancy/Breastfeeding (current or planned during the next month)
• Inability to complete study procedures, such as questionnaires that are only available/validated in English
• Other known untreated sleep fragmenting disorder, such as periodic limb movement disorder, or narcolepsy
• Unwilling or unable to withhold CPAP during polysomnography
• Presence of tracheostomy
• Hospitalization within the past 90 days
• Allergy to the study drug
• Regular use of opioids, or benzodiazepines
• Chronically using study drug or other hypnotic
• Significant circadian rhythm disorder or sleepwalking as an adult
• Active illicit substance use or >3 oz nightly alcohol use
• Prisoners
• Cognitive impairment, unable to provide consent, or unable to carry out research procedures
• Safety concern based on MD judgment

Related Conditions & MeSH terms

• Obstructive Sleep Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Drug:
• Eszopiclone 2 mg
Eszopiclone tablet (encapsulated)
• Placebo
Sugar capsule manufactured to match encapsulated Eszopiclone

Locations

Country	Name	City	State
United States	UC San Diego; Altman Clinical and Translational Research Institute Building	La Jolla	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Diego	American Academy of Sleep Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Sleep Apnea Traits with special focus on arousal threshold	Quantified from routine polysomnography data.	day1 of study drugs
Other	Average total sleep time per night	Based on actigraphy	days 2-14 after initiation of study drugs
Primary	Mean use per night of continuous positive airway pressure (CPAP)	Based on device recorded usage	days 2-14 after initiation of study drugs
Secondary	Alternative measures of CPAP usage	E.g. percentage of nights with CPAP >4h	days 2-14 after initiation of study drugs
Secondary	Response Speed	Based on 10-minute Psychomotor vigilance task (PVT)	days 2-14 after initiation of study drugs
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SDA) instrument	Based on response pattern scoring, the PROMIS 8-item SDA score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep disturbance.	days 2-14 after initiation of study drugs
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment (SRI) instrument	Based on response pattern scoring, the PROMIS 8-item SRI score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.	days 2-14 after initiation of study drugs
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue instrument	Based on response pattern scoring, the PROMIS 8-item Fatigue score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.	days 2-14 after initiation of study drugs
Secondary	Epworth Sleepiness Scale (ESS)	The ESS is an 8-item instrument assessing the likelihood of dozing off in 8 different situations with points for each item ranging from 0 to 3 (0 = would never doze off; 3 = high chance of dozing off). The points for each item are summed up, thus the total score ranges from 0 to 24, with higher ESS scores indicating greater sleepiness.	days 2-14 after initiation of study drugs
Secondary	Apnea Hypopnea Index	The AHI is a measure of sleep apnea severity and is defined as the number of apneas and hypopneas per hour of sleep.	day1 of study drugs
Secondary	Mean Blood Pressure (mmHg)	Average of two in-office blood pressure measurements	day 14 after initiation of study drugs